# A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

> **NCT05029622** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 66 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Triptorelin Pamoate

## Key facts

- **NCT ID:** NCT05029622
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-10
- **Primary completion:** 2022-08-21
- **Final completion:** 2023-02-13
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029622, "A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05029622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*